AxoGen (AXGN) Projected to Release Quarterly Earnings on Wednesday

AxoGen (NASDAQ:AXGN) is expected to be releasing its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.1313 per share and revenue of $73.18 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 8:00 AM ET.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.12 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. The firm had revenue of $69.73 million during the quarter, compared to analyst estimates of $67.10 million. On average, analysts expect AxoGen to post ($0.44) EPS for the current fiscal year and $0.09 EPS for the next fiscal year.

AxoGen Price Performance

NASDAQ:AXGN opened at $38.06 on Monday. AxoGen has a twelve month low of $17.14 and a twelve month high of $52.91. The stock has a fifty day simple moving average of $43.24 and a 200-day simple moving average of $42.16. The company has a market cap of $2.05 billion, a price-to-earnings ratio of -55.97 and a beta of 1.17. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07.

Analyst Upgrades and Downgrades

AXGN has been the subject of several research analyst reports. Canaccord Genuity Group lifted their price target on shares of AxoGen from $50.00 to $55.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Jefferies Financial Group reiterated a “buy” rating and issued a $55.00 target price on shares of AxoGen in a report on Wednesday, July 29th. Wall Street Zen cut AxoGen from a “buy” rating to a “hold” rating in a research note on Saturday, September 26th. Lake Street Capital restated a “buy” rating on shares of AxoGen in a research note on Monday, October 5th. Finally, Raymond James Financial lifted their target price on AxoGen from $48.00 to $53.00 and gave the stock an “outperform” rating in a report on Friday, September 25th. Twelve research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, AxoGen currently has an average rating of “Moderate Buy” and an average price target of $51.27.

Insider Activity at AxoGen

In other AxoGen news, Director Joseph A. Tyndall sold 3,500 shares of the firm’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $49.70, for a total value of $173,950.00. Following the transaction, the director owned 10,650 shares in the company, valued at approximately $529,305. This trade represents a 24.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marc A. Began sold 67,500 shares of AxoGen stock in a transaction on Monday, August 10th. The stock was sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the sale, the executive vice president directly owned 50,135 shares in the company, valued at approximately $2,373,390.90. This trade represents a 57.38% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 98,503 shares of company stock valued at $4,656,947. 2.44% of the stock is owned by corporate insiders.

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.